Paper Details

  1. Home
  2. Paper Details

Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors.

Author: BrecciaMassimo, ChistoliniAntonio, Di PrimaAlessio, FioriLuciano, ScalzulliEmilia, SerraoAlessandra

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment, increasing 10-year survival rates to 80%. Long-term TKI use, especially with second-generation TKIs, has led to the management of various side effects and comorbidities like atrial fibrillation or venous thromboembolism (VTE).
Paper Details　
Original Abstract of the Article :
In the last decades, the chronic myeloid leukemia (CML) therapeutic landscape has changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs), with 10-year survival rates improving to up to 80%. Long-lasting TKI treatment, in particular with second-generation TKIs, has enabled cl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40261-020-00980-w

データ提供：米国国立医学図書館（NLM）

Chronic Myeloid Leukemia: A Changing Landscape

The world of chronic myeloid leukemia (CML) treatment has undergone a remarkable transformation in recent decades, thanks to the arrival of tyrosine kinase inhibitors (TKIs). These powerful drugs have significantly improved the survival rates for CML patients, reaching an impressive 80% over a 10-year period. The long-term use of TKIs, particularly the second-generation ones, has allowed doctors to effectively manage various side effects and co-morbidities, such as atrial fibrillation and venous thromboembolism (VTE).

The Long-Term Effects of TKIs

This research highlights the positive impact of TKIs on CML treatment, demonstrating their ability to improve survival rates and manage associated complications. The study sheds light on the long-term implications of TKIs, emphasizing the need for continued monitoring and management of potential side effects.

Navigating the Desert of CML Treatment

This study is like a refreshing oasis in the vast desert of CML research. It provides valuable insights into the long-term effects of TKIs, guiding doctors and patients towards a more effective and manageable treatment journey. While the study presents a positive outlook, it also reminds us of the importance of ongoing research to address potential side effects and optimize treatment strategies for CML.

Dr.Camel's Conclusion

TKIs have revolutionized CML treatment, but the journey is still ongoing. We must continue to explore the long-term effects of these drugs and develop strategies for managing potential complications. This research is a beacon of hope in the vast desert of CML research, guiding us towards a future where more patients can thrive.

Date :
  1. Date Completed 2021-01-26
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

33090357

DOI: Digital Object Identifier

10.1007/s40261-020-00980-w

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.